Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More

MENU

Pancreatic Cancer Clinical Trials

Newly diagnosed, previously untreated patients with metastatic pancreatic cancer

A Phase 1a/b Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy (NCI# NCT04068896)

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (NCI# NCT03611556)

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT) (NCI# NCT04233866)

Newly diagnosed, previously untreated patients with localized pancreatic cancer who are candidates for surgical resection

Initial Feasibility Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer (NCI# NCT02843945)

RT-155: Utilizing Pulsed Low-dose-rate (PLDR) Radiation to Prevent de Novo Stromal Activation; a Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial (NCI# NCT04452357)

Non-interventional studies, correlative and biomarker studies

A Pilot Study of Caregiver Adjustment and Quality of Life among Pancreatic Cancer Patients

Patients with previously treated metastatic pancreatic cancer

Fox Chase has a robust phase I clinical trials program with a number of trials open for those who have been previously treated for metastatic pancreatic cancer. You can search for open phase I clinical trials for pancreatic cancer here.

Connect with Fox Chase